Thermo Fisher Scientific Inc. announced a long-term target of seven percent [1] annual organic revenue growth during its Investor Day event on May 20, 2026 [3].
These projections signal the company's intent to maintain aggressive expansion in the life sciences and diagnostics sectors. By establishing these benchmarks, the firm aims to provide shareholders with a clear value-creation strategy and a roadmap for industry leadership.
The event took place in New York City, starting at 9 a.m. ET [4, 5]. Led by Chairman and CEO Marc N. Casper, the company used the forum to outline its growth outlook and operational strategy [1, 2].
In addition to the revenue target, Thermo Fisher set a goal for adjusted earnings-per-share growth in the low-teens percent [2]. This dual focus on both top-line organic growth and bottom-line earnings efficiency is intended to demonstrate the company's scalability over the long term [1, 2].
Executives focused on how the company's current market position allows for such targets. The strategy involves leveraging its existing portfolio to capture emerging opportunities in the science and healthcare markets, a move designed to secure sustainable growth for the foreseeable future [1, 2].
“Thermo Fisher announced a target of 7% annual organic revenue growth.”
By committing to specific percentage targets for organic revenue and earnings-per-share, Thermo Fisher is attempting to stabilize investor expectations amid a volatile global biotech market. These goals suggest the company believes its current scale provides a competitive moat that can withstand macroeconomic headwinds while continuing to expand its footprint in laboratory equipment and diagnostics.
